Brand Name | Status | Last Update |
---|---|---|
venclexta | New Drug Application | 2024-07-12 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
lymphoid leukemia | — | D007945 | C91 |
Expiration | Code | ||
---|---|---|---|
VENETOCLAX, VENCLEXTA, ABBVIE | |||
2026-05-15 | ODE-239 | ||
2025-11-21 | ODE-211 | ||
2025-06-08 | ODE-185 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Venetoclax, Venclexta, Abbvie | |||
9539251 | 2033-09-06 | U-2538 | |
10993942 | 2033-09-06 | U-3114 | |
11110087 | 2033-09-06 | U-3222, U-3223 | |
11413282 | 2033-09-06 | U-3412 | |
11590128 | 2033-09-06 | U-3548 | |
11369599 | 2032-05-23 | DP | |
8722657 | 2032-01-29 | DP | |
10730873 | 2031-11-21 | DP | |
8546399 | 2031-06-27 | DS, DP | |
9174982 | 2030-05-26 | U-2323, U-2445, U-2446, U-2537 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Leukemia | D007938 | — | C95 | 166 | 223 | 43 | 3 | 62 | 424 |
Myeloid leukemia acute | D015470 | — | C92.0 | 138 | 154 | 25 | 2 | 44 | 306 |
Myeloid leukemia | D007951 | — | C92 | 117 | 130 | 20 | 2 | 40 | 264 |
Lymphoid leukemia | D007945 | — | C91 | 46 | 84 | 21 | 1 | 20 | 149 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 32 | 65 | 22 | 2 | 17 | 126 |
Heart failure | D006333 | HP_0001635 | I50 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lymphoma | D008223 | — | C85.9 | 69 | 78 | 8 | — | 3 | 130 |
Myelodysplastic syndromes | D009190 | — | D46 | 56 | 47 | 2 | — | 3 | 82 |
Preleukemia | D011289 | — | — | 46 | 34 | 2 | — | 1 | 63 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 40 | 23 | 1 | — | 2 | 53 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | — | 22 | 33 | 2 | — | 8 | 52 |
Syndrome | D013577 | — | — | 35 | 31 | 1 | — | — | 50 |
Neoplasms | D009369 | — | C80 | 28 | 21 | 4 | — | 4 | 47 |
Mantle-cell lymphoma | D020522 | — | — | 15 | 25 | 2 | — | 1 | 36 |
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 22 | 14 | 1 | — | 2 | 31 |
B-cell lymphoma | D016393 | — | — | 22 | 13 | 1 | — | 2 | 30 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Recurrence | D012008 | — | — | 22 | 30 | — | — | 1 | 40 |
Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 21 | 21 | — | — | 1 | 30 |
Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 21 | 20 | — | — | 1 | 29 |
Hematologic neoplasms | D019337 | — | — | 20 | 14 | — | — | 3 | 26 |
Follicular lymphoma | D008224 | — | C82 | 14 | 12 | — | — | 1 | 21 |
Myeloproliferative disorders | D009196 | — | D47.1 | 9 | 9 | — | — | 1 | 16 |
Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 3 | 9 | — | — | 2 | 12 |
Precursor t-cell lymphoblastic leukemia-lymphoma | D054218 | — | — | 3 | 11 | — | — | — | 12 |
B-cell lymphoma marginal zone | D018442 | — | C88.4 | 8 | 6 | — | — | — | 12 |
Myelomonocytic leukemia acute | D015479 | — | C92.5 | 6 | 9 | — | — | — | 10 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Carcinoma | D002277 | — | C80.0 | 4 | — | — | — | — | 4 |
Prostatic neoplasms | D011471 | — | C61 | 3 | — | — | — | — | 3 |
Castration-resistant prostatic neoplasms | D064129 | — | — | 2 | — | — | — | — | 2 |
Hodgkin disease | D006689 | — | C81 | 1 | — | — | — | 1 | 2 |
Myeloid sarcoma | D023981 | — | C92.3 | 2 | — | — | — | — | 2 |
Non-small-cell lung carcinoma | D002289 | — | — | 2 | — | — | — | — | 2 |
Aggression | D000374 | EFO_0003015 | — | 2 | — | — | — | — | 2 |
T-cell lymphoma cutaneous | D016410 | — | — | 1 | — | — | — | 1 | 2 |
Gata2 deficiency | D000077428 | — | D46.22 | 2 | — | — | — | — | 2 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Frailty | D000073496 | — | R53.1 | — | — | — | — | 1 | 1 |
Plasma cell leukemia | D007952 | — | C90.1 | — | — | — | — | 1 | 1 |
Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | — | — | — | — | 1 | 1 |
Eye abnormalities | D005124 | HP_0000478 | Q15.9 | — | — | — | — | 1 | 1 |
Chromosome aberrations | D002869 | Orphanet_68335 | — | — | — | — | — | 1 | 1 |
Chromosome disorders | D025063 | EFO_0003831 | Q99.9 | — | — | — | — | 1 | 1 |
Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | — | — | 1 | 1 |
Sudden death cardiac | D016757 | EFO_0004278 | — | — | — | — | — | 1 | 1 |
Death | D003643 | PATO_0001422 | — | — | — | — | — | 1 | 1 |
Drug common name | Venetoclax |
INN | venetoclax |
Description | Venetoclax is a member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion. It has a role as an apoptosis inducer, an antineoplastic agent and a B-cell lymphoma 2 inhibitor. It is a member of oxanes, a N-sulfonylcarboxamide, an aromatic ether, a pyrrolopyridine, a member of monochlorobenzenes, a N-arylpiperazine, a N-alkylpiperazine and a C-nitro compound. |
Classification | Small molecule |
Drug class | bcl-2 (B-cell lymphoma 2) inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1 |
PDB | — |
CAS-ID | 1257044-40-8 |
RxCUI | — |
ChEMBL ID | CHEMBL3137309 |
ChEBI ID | — |
PubChem CID | 49846579 |
DrugBank | DB11581 |
UNII ID | N54AIC43PW (ChemIDplus, GSRS) |